Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9920173 | 0.81 | RAB9A (0.50) | KMT2AMEN1RAB9ANPC1ACACB | |
| SCHEMBL10824702 | 0.76 | KMT2A (0.59) | KMT2AMEN1RAB9ANPC1RXRA | |
| SCHEMBL23074666 | 0.75 | MEN1 (0.47) | KMT2AMEN1RAB9ANPC1RXRA | |
| SCHEMBL14579974 | 0.74 | MEN1 (0.62) | KMT2AMEN1RAB9ANPC1RXRA | |
| SCHEMBL10593412 | 0.74 | MEN1 (0.62) | KMT2AMEN1RAB9ANPC1RXRA | |
| SCHEMBL22831355 | 0.74 | KCNH2 (0.53) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL84461 | 0.74 | HRH3 (0.59) | KMT2AMEN1SMN1; SMN2KDM4E | |
| SCHEMBL12227194 | 0.73 | RXRA (0.49) | KMT2AMEN1RAB9ARXRARXRB | |
| SCHEMBL13531974 | 0.73 | GAA (0.51) | KMT2AMEN1RAB9ANPC1RXRA | |
| SCHEMBL20004355 | 0.73 | MEN1 (0.53) | KMT2AMEN1RAB9ARXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | KMT2A 533/4885MEN1 436/4885RAB9A 1684/4885 |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | KMT2A 628/4885MEN1 440/4885RAB9A 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.